The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

GLP-1 receptor agonists, initially developed for type 2 diabetes, have gained traction for weight loss and cardiovascular risk reduction. However, doctors say their use in type 1 diabetes patients ...

With many companies racing to market rival versions of semaglutide in cheaper and easier-to-take forms, as well as mounting evidence that that GLP-1 drugs can target a host of health conditions ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

The class of drugs – GLP-1 receptor agonists – has been around for two decades as a diabetes medication. Their popularity as a tool for weight loss skyrocketed after the US Food and Drug ...